Sugi Predict

Sugi Predict / Compounds / Pramiverine

Pramiverine

Pramiverine

SCHEMBL24038

CC(C)NC1CCC(c2ccccc2)(c2ccccc2)CC1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ OPRM1 P35372 5/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GRIN2D O15399 1/20 0.40
▸ GRIN3B O60391 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ GRIN1 Q05586 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ GRIN2A Q12879 1/20 0.40
▸ GRIN2B Q13224 1/20 0.40
▸ GRIN2C Q14957 1/20 0.40
▸ GRIN3A Q8TCU5 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ OPRL1 P41146 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pramiverine SCHEMBL10728097 0.98 GAA (0.46) GAAL3MBTL1CYP2D6OPRM1MEN1
Pramiverine SCHEMBL1651369 0.97 GAA (0.45) GAAL3MBTL1CYP2D6OPRM1MEN1
Pramiverine SCHEMBL10729752 0.79 LMNA (0.42) GAAL3MBTL1CYP2D6OPRM1KCNH2
SCHEMBL8992487 0.75 OPRM1 (0.47) CYP2D6OPRM1MEN1CYP2C9KMT2A
SCHEMBL11763463 0.73 MAPK1 (0.44) OPRM1SMN1; SMN2MAPK1OPRL1ALOX15
SCHEMBL8101425 0.72 OPRM1 (0.50) CYP2D6OPRM1MEN1CYP2C9KMT2A
SCHEMBL9274058 0.70 GRIN2B (0.51) GAAL3MBTL1CYP2D6MEN1KMT2A
SCHEMBL9274061 0.70 GRIN2B (0.51) GAAL3MBTL1CYP2D6MEN1KMT2A
SCHEMBL8093890 0.69 OPRM1 (0.47) GAACYP2D6OPRM1MEN1CYP2C9
SCHEMBL7944535 0.69 OPRM1 (0.47) CYP2D6OPRM1MEN1CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233997-A Tetrahedral antibodies 生物分子控股有限责任公司 2024-12-31 — — CN claimed
EP-4463485-A2 TETRAHEDRAL ANTIBODIES Biomolecular Holdings LLC (US) 2024-11-20 — — EP claimed
WO-2023137373-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-20 — — WO claimed
WO-2023137387-A2 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-20 — — WO claimed
US-20230220116-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-13 — — US claimed
US-20230220115-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-13 — — US claimed
EP-4178615-A1 TETRAHEDRAL ANTIBODIES Biomolecular Holdings LLC (US) 2023-05-17 — — EP claimed
US-11225490-B2 Prodrugs of secondary amine compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2022-01-18 — — US claimed
WO-2022011358-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2022-01-13 — — WO claimed
US-11066459-B2 Hybrid immunoglobulin containing non-peptidyl linkage BIOMOLECULAR HOLDINGS LLC (US) 2021-07-20 — — US claimed
WO-2013088255-A1 PRODRUGS OF SECONDARY AMINE COMPOUNDS ALKERMES PHARMA IRELAND LIMITED (IE) 2013-06-20 — — WO claimed
WO-2012088441-A1 MULTI- API LOADING PRODRUGS ALKERMES, INC. (US) 2012-06-28 — — WO claimed
EP-1879578-A4 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV PHARMACEUTICAL INC (US) 2009-05-13 — — EP claimed
EP-1879578-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV Pharmaceutical Inc. (US) 2008-01-23 — — EP claimed
WO-2006102029-A9 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV PHARMACEUTICAL INC (US) 2006-12-07 — — WO claimed
WO-2006102029-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE DOV PHARMACEUTICAL, INC. (US) 2006-09-28 — — WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
EP-0193056-B1 COMBINATION OF FLUPIRTIN WITH SPASMOLYTICS HAVING AN ANTICHOLINERGIC EFFECT ASTA Pharma Aktiengesellschaft (DE) 1989-06-07 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066459-B2 Hybrid immunoglobulin containing non-peptidyl linkage FCGR3B, FCGR2A, SCLY GAA 4579/4885L3MBTL1 866/4885CYP2D6 4504/4885
US-20230220115-A1 TETRAHEDRAL ANTIBODIES FCGR3B, FCGR2A, FCGR1A GAA 2680/4885L3MBTL1 1415/4885CYP2D6 4821/4885
US-20230220116-A1 TETRAHEDRAL ANTIBODIES FCGR3B, FCGR2A, FCGR1A GAA 2680/4885L3MBTL1 1415/4885CYP2D6 4821/4885
US-11225490-B2 Prodrugs of secondary amine compounds HNMT, MAOB, UGT1A1 GAA 909/4885L3MBTL1 3572/4885CYP2D6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.